Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx) by Just, K.S. et al.
PHARMACOGENETICS
Medical education in pharmacogenomics—results from a survey
on pharmacogenetic knowledge in healthcare professionals
within the European pharmacogenomics clinical implementation
project Ubiquitous Pharmacogenomics (U-PGx)
Katja Susanne Just1 & Michael Steffens1 & Jesse Joachim Swen2 &
George P. Patrinos3 & Henk-Jan Guchelaar2 & Julia Carolin Stingl1,4
Received: 28 December 2016 /Accepted: 15 June 2017 /Published online: 2 July 2017
# The Author(s) 2017. This article is an open access publication
Abstract
Purpose Due to the diversitywithin Europe, the implementation
of pharmacogenomic testing in clinical practice faces specific
challenges. In the context of the European pharmacogenomics
implementation project BUbiquitous Pharmacogenomics^ (U-
PGx; funded by the European Commission), we studied the
current educational background.
Methods We developed a questionnaire including 29 ques-
tions. It was spread out to healthcare professionals working
at the future implementation sites (in Austria, Greece, Italy,
Netherlands, Slovenia, Spain and Great Britain) of the U-PGx
project in preparation of an educational programme. Aim of
the survey was to analyse the current educational situation at
the implementation sites.
Results In total, 70 healthcare professionals participated in the
survey. Of participants, 84.3% found pharmacogenomics rele-
vant to their current practice, but experience was still rare. More
than two-thirds (65.7%) did not order nor recommend a
pharmacogenomic test in the past year. This was mainly attrib-
uted to not having enough knowledge on pharmacogenomics
(40.0%). Needs were identified in application of
pharmacogenomics (identifying drugs 41.4%, interpreting test
results 37.2%) as well as in underlining mechanisms (better
knowledge on drug metabolism 67.1%, better knowledge on
basic principles of pharmacogenomics 60.0%).
Conclusions This study analysed the specific attitudes, expe-
rience and education on pharmacogenomics of future users.
There was a general positive attitude and interest towards
pharmacogenomic testing. However, the grade of own expe-
rience, and knowledge about application and interpretation of
pharmacogenomics caused uncertainty. Thus, education and
training programmes may be helpful for implementation of
pharmacogenomics at a homogenous level within Europe.
Keywords Pharmacogenomics . Pharmacogenetics . Clinical
pharmacology . Cultural diversity . Medical education
Introduction
In the context of the study, Ubiquitous Pharmacogenomics,
pharmacogenomic testing was understood mainly for assess-
ment of the variability of genes affecting drug disposition,
metabolism and drug transport leading to individual responses
to drugs [1]. By genotyping, testing for established gene var-
iants, it is assumed to improve drug efficacy and safety [2, 3].
Pre-emptive, prospective, genotyping to make individualised
drug therapy feasible is seen to contribute to personalised
medicine [4]. Pre-emptive genotyping is thereby thought to
be used to decide on the right drug for the right patient as well
as the right dose [5]. Potential benefits of pharmacogenomics
(PGx) have been defined such as predicting intended response
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to medication by more accurate dosing, avoiding adverse drug
reactions and therefore enhancing drug safety and reducing
health care costs [6]. However, in the field of PGx, it is chal-
lenging to collect sufficient sample sizes for analysing effec-
tiveness in clinical trials owing the rarity of PGx variants and
population heterogeneity [2, 7].
In the USA, there are medical centres with large current
programmes implementing pharmacogenomics into clinic
using pre-emptive testing facing specific challenges [5]. The
need of s tandard ised educat ion programmes on
pharmacogenomics for pharmacists and physicians was ad-
dressed [8, 9]. Concordantly, some Pharmacogenomics
Educational Programs were established [5, 10–14].
In Europe, the uptake of PGx into clinical care seems to fall
behind [15]. Challenges in establishing pharmacogenomics
into clinic in Europe have been identified such as cost-
effective studies with a need for data and tool sharing between
countries, training programmes and education of medical staff
[16–18] also addressing the diversity of health care systems
within Europe. The availability of adequate lab tests is a cru-
cial step in increasing the uptake of pharmacogenomics into
clinic [19, 20]. Different backgrounds and specialities in
health care might show varying affinity to pharmacogenomic
diagnostic [9, 21]. Furthermore, different payment and
funding structures compared to the USA are a challenge for
clinical utility of PGx in Europe and within different European
countries [16, 22]. In this context, one has to see the impor-
tance of a harmonised educational environment in
pharmacogenomics and its clinical application in Europe, as
knowledge and education have been defined several times as
crucial step for successful implementation [5, 8–10, 12, 16,
23–25].
The Ubiquitous Pharmacogenomics (U-PGx) project
which was funded by the European Commission is aiming
to implement pre-emptive genotyping in seven existing
European health care environments (implementation sites)
[1, 23, 26]. In this context, education of participating
health care professionals and further is in the focus of the
project. However, diversity of health care systems might be
a challenging factor. We intended to study the current
knowledge about pharmacogenomics and the attitudes of
clinicians towards pharmacogenomic testing at seven im-
plementation sites in European countries in which the pro-
ject will be run.
Materials
We conducted an internet-based survey on knowledge and
attitude towards PGx among 70 health care professionals re-
lated to the U-PGx implementation project. This survey was
voluntary and participants were informed about anonymity
and potential use of the results for publication. Aim of the
survey was to analyse the current situation at implementation
sites involved in the U-PGx project. Furthermore, results of
the survey should act as a basis for development of an educa-
tional programme enabling PGx testing in clinic. Therefore, a
questionnaire with 29 questions was designed. The question-
naire was composed in a stepwise procedure, including inter-
nal and external review steps. Some questions were included
on basis of a search of literature to make the questionnaire
comparable to others. When a first draft of the questionnaire
was ready, it was sent to the seven implementation site leaders
for feedback, and their comments were subsequently included.
The final questionnaire was approved by all clinical sites.
The questionnaire was piloted in a cohort of clinicians in
Germany (final questionnaire is provided in the supplementa-
ry material).
The survey was designed using SurveyGizmo© and was
made accessible via the official U-PGx website in a password-
protected manner. Since pharmacogenomics testing will be im-
plemented in different clinical sites in the context of the U-PGx
study, this survey was performed prior to the start of the imple-
mentation study involving clinicians at the clinical sites working
in direct patient contact and with those, who are deciding about
drug treatment and therapy adjustment. As the number of per-
sons who were reached by the pharmacogenomics testing ser-
vice varied at the different sites, the number of clinicians from
each country to be contacted was different. The implementation
sites were in Austria, Greece, Italy, Netherlands, Slovenia,
Spain, and the UK. The survey was online for two and a half
months (from June 13 to August 31 2016). Analyses were con-
ducted using the SurveyGizmo© report. Where necessary, this
analysis was supplemented with analysis conducted in excel.
Results
In total, 70 surveys were answered completely (responder rate
27.5%), from seven implementation sites involved in U-PGx.
The implementation sites were very different in size,
organisational structure, and medical orientation. Characteristics
and numbers of participants in the survey are seen in Table 1.
Experience and attitude
The majority of participants agreed that PGx was important in
their current practice (84.3%, agree totally and agree slightly;
missing 15.7% disagree totally and disagree slightly), but
65.7% had not ordered nor recommended a PGx test in the
past year. In general, drug dosing was based on multiple fac-
tors with pharmacogenomics mentioned as one of the factors
taken into account in 18.6% (Fig. 1). The main answers for the
reasons why they were not using PGx tests in daily practice
were Bnot applicable^ and Bnot enough knowledge about PGx
testing^ (each 40.0%, multiple answers possible), followed by
lack of reimbursement/insurance coverage (22.9%), and
1248 Eur J Clin Pharmacol (2017) 73:1247–1252
uncertainty about the value of testing (17.1%). Of those that
had been ordering a test during the past year (34.3% of the
total), a large majority felt that the test results have been useful
(91.7%). For potential reasons why pharmacogenomics tests
would be ordered, the most often given answer was Bnot ap-
plicable^ (41.4%), followed by Bfor research purposes^ and
Bfor preventing or explaining side effects^ (25.7% each), and
dose adjustments (22.9%).
Knowledge and educational experience
In majority, participants felt familiar with classical genetics,
pharmacology and drug metabolism, and the role of drug
metaboliser phenotypes (78.6, 85.8 and 75.7%, respectively,
agree totally and agree slightly). In PGx and interpreting PGx
test results, participants felt slightly less familiar (61.5 and
51.4%, Fig. 2).
Nearly on all topics, university was the most important
resource for learning (with mainly >50% confirming the im-
portance, multiple answers possible). Resources of postgrad-
uate education, like residency/junior staff membership, con-
ferences, journals or internet were rarely mentioned by more
than 30% (Fig. 3).
Knowledge testing
Performance in knowledge testing in general showed 41% of
questions to be answered correctly, 36.6% wrong, and in
22.4% participants indicated Bno idea^. According to ques-
tion, answering varied extensively, with for one question
54.3% answering no idea (Q13), one question with 75.7%
correct answer (Q12), and one question with 71.5% incorrect
answer (Q15) (Fig. 4).
Educational needs
Almost half of the participants (41.4%) disagreed to be
able to identify drugs that require PGx tests (disagree
Fig. 1 Factors that drug dosing is
predominantly based. Given in
percentages. Multiple answers
possible
Table 1 Characteristics of the healthcare professionals participating in
the U-PGx survey (n = 70, involved in implementation project)
Gender Female 52.9% (37)
Male 47.1% (33)
Age (years) Mean (range) 39 (25–67)
profession Physician 75.7% (53)
Pharmacist 15.7% (11)
Othera 8.6% (6)









Country Austria 18.6% (13)






Data given in percentage (absolute number), except age (given as mean
(range))
a Includes lab personal
b Not distinguishable
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totally and disagree slightly). And, 37.2% disagreed in
being able to use test results accordingly to adjust drug
therapy. On the question, Bwhat knowledge would you
need to utilize pharmacogenomics for adjustment of ther-
apy?^, 67.1% of participants included better knowledge
on drug metabolism, 60.0% better knowledge on the basic
concepts of PGx, 55.7% a better evidence that PGx im-
proves clinical outcomes, 52.9% a better knowledge on
genetics, 51.4% better knowledge on pharmacology, and
more than 40% agreed that they would need support of
their working institution (44.3%) and a better ability to
apply their knowledge (41.4%).
As preferred learning format on PGx for the future,
accredited learning courses (60.0%) and continuing med-
ical education-accredited workshops (55.7%) were picked
by over 50% of participants. Furthermore, e-learning
courses (47.1%), patient cases and scientific articles
(each 44.3%) were mentioned by more than 40% of
participants.
Discussion
With this survey in preparation of the implementation of
pharmacogenomics diagnostics in the U-PGx project in
Europe, we analysed the specific attitudes, experience and
knowledge on PGx in future users [1, 23]. We found a general
interest and belief of usefulness of PGx testing in participants.
However, the application and interpretation of PGx, when and
whom to test, and how to use the results and give therapy
recommendations or therapy adjustments, caused uncertainty
and needs further improvement. Those results are comparable
to results of questionnaires with pharmacists and physicians
on pharmacogenomics [8, 9], even though our cohort was
slightly more used to application of pharmacogenomics. For
example, a survey among Dutch pharmacists revealed 14.7%
recent users of PGx diagnostics [27], whereas in our cohort,
the percentage was with 34.3% higher. However, the cohort
Fig. 3 Resources for learning
medical topics. Given in
percentages. For each topic,
multiple answers possible
Fig. 4 Knowledge testing. Q12: What may be the consequence of a PGx
polymorphism? Q13: The EMA currently includes PGx information in
the drug labels of how many medications? Q14: What does a PM
phenotype indicate? Q15: A person who is a PM for CYP2D6 gets a
medication that induces CYP2D6. What may be a consequence?
Fig. 2 Self-perceived knowledge of participants to our survey. Given in
percentages
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presented consists of future adopters of the PGx implementa-
tion study project U-PGx and therefore do not represent the
clinical situation on knowledge and attitudes towards PGx in
general in Europe.
Implementation sites and their organisational structure
to implement PGx varied extensively, thus leading to dif-
ferent sample sizes from each implementation site and
country, respectively. Accordingly, this was a heteroge-
neous group of future adopters of PGx from different med-
ical backgrounds with age and number of work experience
ranging extensively. The common background for all
participants/study centres was that the use of PGx was
already present before the beginning of the study, thereby
analysing a collective of future adopters prior to the imple-
mentation project. The situation therefore may not be
regarded to be representative for the general situation in
pharmacogenetic testing within Europe. Respecting the
heterogeneity, this survey used a large number of questions
on characteristics of participants. Furthermore, this survey
was designed to serve as a basis for development of an
educational programme within the same European imple-
mentation study, addressing the same group of participants
and therefore focuses strongly in numbers of questions on
education, educational experience, and educational needs.
Results on attitude towards PGx, and interest and useful-
ness of PGx tests, are probably not generalizable, although in
line with results from previous surveys [8, 9, 27]. As depicted
above, this cohort was derived from implementation sites
within a study trial where some of them are already used to
apply PGx in specific medical problems in patient care.
Accessory, those results may be partially explained by social
desirability bias [28], as participants knew that they would be
future users of PGx tests within a study trial.
Also within the knowledge and educational experience
section, this social desirability bias may explain the results
partially. For example, the majority felt familiar with phar-
macology and drug metabolism but on the same side in the
educational needs section, wished more education as basis
for applying PGx in clinic. A strength of this study is that
knowledge was shortly tested, which is not commonly seen
in surveys. In general, the grade of knowledge about ap-
plication and interpretation of pharmacogenomics caused
uncertainty and was not at a homogenous level within
healthcare professionals working at the clinical sites. This
is in concordance with data derived from other European
surveys. In a survey on pharmacists and physicians in
Greece, over half of the respondents appraise themselves
to be unable to explain PGx test results [25] characterising
education as a critical step in clinical implementation.
Concerning pharmacogenomics education in Universities
in South East Europe, a heterogeneous situation was re-
ported and PGx is only rarely delivered as a stand-alone
course [24]. In this study, residents and specialist answered
with above 80% that they would be unable to interpret test
results. And, in a survey among Dutch pharmacists, just
27% felt themselves to be able to interpret test results and
to give advises or to treat the patient based on the results
[27].
Participants were generally open for education in PGx,
which is again in concordance with published data [8, 9,
25]. As specifically the application of PGx in clinic causes
uncertainty, one would need educational programmes that fo-
cus on clinical implementation. An accreditation of learning
would be desired. So far, medical knowledge seems to be
mainly generated at universities and the role of postgraduate
medical education of pharmacogenomics remains still low. As
the importance of education for implementation of PGx into
clinics is underlined manifold [5, 8, 9, 11, 17, 23], this might
be crucial. A large educational effort has to be done to train for
application of this complex topic [10, 12, 29]. Even our spe-
cific cohort of participants, who were already opened for PGx
and its use in clinic, showed a need for education especially on
the actual use of pharmacogenomics, knowing whom and
when to test, interpreting test results and giving therapy
recommendations.
As pointed out, there are known challenges in conducting
trials in pharmacogenomics [2, 7]. This subject might be even
more complicated in European countries, not only owing the
occurrence of pharmacogenomics variance [29] and the lack
of educational programmes in Europe [24] but also due to the
heterogeneity of health care systems and number of spoken
languages. Especially in the field of pharmacogenomics lays
the chance to reduce adverse drug reaction and optimise drug
therapy [30, 31]. But, prospective randomised controlled clin-
ical trials are needed using multi-centre international collabo-
rations [32]. A retrospective study including 1017 randomised
controlled trials found that 25% of initiated trials remained
discontinued. The main reason was patient recruitment with
administrative reasons among the most common [33].
European multicentre studies might have an even more in-
creased problem with administrative reasons due to the diver-
sity in political and health systems.
There is a need for European studies, especially in the field
of implementing pharmacogenomics into clinic. Realising
studies as well as implementation with a European standard
remains challenging, and pitfalls such as the diversity of
health care systems and educational needs should be attended.
However, this challenge has to be taken to exist in the com-
petitive field of research.
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